Omega Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Omega Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q2 2024.
Omega Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 284 %, a 436% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	284	+231	+436%	Jun 30, 2024
Q1 2024	208	+180	+643%	Mar 31, 2024
Q4 2023	129	+103	+403%	Dec 31, 2023
Q3 2023	86.9	+65.9	+315%	Sep 30, 2023
Q2 2023	53	+36.2	+216%	Jun 30, 2023
Q1 2023	28	+5.7	+25.6%	Mar 31, 2023
Q4 2022	25.6			Dec 31, 2022
Q3 2022	20.9			Sep 30, 2022
Q2 2022	16.8			Jun 30, 2022
Q1 2022	22.3			Mar 31, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.